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ABSTRACT
Objective: The present paper describes a simple, accurate, and precise reversed-phase high-performance liquid chromatography (HPLC) method for 
rapid and simultaneous quantification of cabozantinib (CZT) and nivolumab (NVM) in bulk and pharmaceutical dosage form.
Methods: The chromatographic separation was achieved on Luna C18 (150 mm×4.6 mm, 3.5 µm). Mobile phase contained a mixture of 0.1% 
orthophosphoric acid and acetonitrile in the ratio of 50:50 v/v, flow rate 1.0 ml/min, and ultraviolet detection at 222 nm.
Results: The proposed method shows a good linearity in the concentration range of 20–300 µg/ml for CZT and 5–75 µg/ml for NVM under optimized 
conditions. Precision and recovery study results are in between 98 and 102%. In the entire robustness conditions, percentage relative standard 
deviation is <2.0%. Degradation has minimum effect in stress condition and solutions are stable up to 24 h.
Conclusion: This method is validated for different parameters such as precision, linearity, accuracy, limit of detection (LOD), limit of quantification 
(LOQ), ruggedness, robustness, and forced degradation study were determined according to the International Conference of Harmonization (ICH) 
Q2B guidelines. All the parameters of validation were found to be within the acceptance range of ICH guidelines. Since there is no HPLC method 
reported in the literature for the estimation of CZT and NVM in pharmaceutical dosage forms, there is a need to develop quantitative methods under 
different conditions to achieve improvement in sensitivity, selectivity, etc.
The author declares the interest to develop a validation and forced degradation for simultaneous quantification of CZT and NVM.
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INTRODUCTION
Cabozantinib (CZT) is a medication used to treat medullary thyroid 
cancer [1] and a second line treatment for renal cell carcinoma [2] among 
others. It is a small molecule [3] inhibitor of the tyrosine kinesis [4] 
c-Met [5,6] and vascular endothelial growth factor receptor 2 [7], and 
also inhibits AXL [8] and RET [9]. It was discovered and developed by 
Evelix’s [10] included in the study.
Nivolumab (NVM) marketed as Opdivo, is a medication used to treat 
cancer [11]. It is used as a first-line treatment for inoperable or metastatic 
melanoma [12] in combination with ipilimumab [13] if the cancer does not 
have a mutation in BRAF as a second-line treatment following treatment 
with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF 
inhibitor [14] as a second-line treatment for squamous non-small cell lung 
cancer [15] and as a second-line treatment for renal cell carcinoma [2]. It 
had not been tested in pregnant women but based on the mechanism of 
action and animal studies, is probably toxic to the baby, it is not known 
if it is secreted in breast milk. Side effects include severe immune-
related inflammation of the lungs, colon, liver, kidneys, and thyroid, and 
there are effects on skin, central nervous system [16], the heart, and the 
digestive system [17]. It is a human IgG4 [18] anti-PD-1 [19] monoclonal 
antibody [20]. NVM works as checkpoint inhibitor [21] blocking a signal 
that would have prevented activated T-cells [22] from attacking the cancer, 
thus allowing the immune system to clear the cancer. It was discovered 
at Medarex [23], developed by Medarex and Ono pharmaceutical, and 
brought to market by Bristol-Myers Squibb [24] and Ono.
To date, there is no literature for current drugs of CZT and NVM for high-
performance liquid chromatography (HPLC) and spectrophotometry. 
Hence, we have to develop stability-indicating simultaneous estimation 




The analysis was performed on Water Alliance e-2695 chromatographic 
system equipped with a quaternary pump and photodiode array 
detector (PDA) detector-2996. Chromatographic software empower-2.0 
was used for data collection.
Chemicals and reagents
Acetonitrile (HPLC grade), orthophosphoric acid (OPA) (HPLC grade), 
and water (HPLC grade) were purchased from Merck (India) Ltd., 
Worli, Mumbai, India. Active pharmaceutical ingredients (APIs) of 
CZT and NVM reference standards were produced from Glenmark 
Pharmaceuticals Private Ltd., Mumbai, India.
Chromatographic conditions
Chromatographic analysis was done using isocratic elution, mobile 
phase in the ratio of acetonitrile:buffer (0.1% OPA) (50:50 v/v) was 
filtered through 0.45 µ membrane filter paper. The flow rate of the 
mobile phase was monitored at 1.0 ml/min and eluents were detected 
at 222 nm. By injecting the volume 10µl with a run time 10min.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.29013
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Selection of wavelength
Using PDA detector, the absorption spectra of the solution of two drugs 
were scanned in the ultraviolet region 200–400nm spectra shown in Fig. 1, 
the spectra of the CZT and NVM shown at different λmax, namely 245.0 and 
273.3 nm, respectively. By overlay of the two spectra combined at 222 nm 
was selected as detection wavelength for HPLC chromatographic method.
Preparation of standard solution
About 200 mg of CZT and 50 mg of NVM working standard taken into 
a 100 ml volumetric flask. Add 70 ml of mobile phase sonicated for 
10 min to dissolve and makeup to the mark with mobile phase. Further, 
diluted each 5 ml of above two solutions to 50 ml with mobile phase.
Preparation of sample solution
Weigh 20 tablets and take the one tablet equivalent weight. Crush 
the 20 tablets into powder form, take 600 mg of sample into a 100 ml 
volumetric flask, and add 70 ml mobile phase sonicated for 30 min after 
that makeup to the mark with mobile phase. Further, dilute 5 ml of 
above solution to 50 ml volumetric flask make up to mark with mobile 
phase. Filter through 0.45 µ nylon syringe filter.
Validation
System suitability
As per the test method, the standard solutions were prepared and 
injected into HPLC system from which the evaluated system suitability 
parameters are found to be within the limits.
Linearity
The ability of the method to produce results those are directly or 
indirectly proportional to the concentration of the analyst in samples 
within the limits.
Fig. 1: Photodiode array detector spectra for cabozantinib and nivolumab
Fig 2: Typical standard chromatogram for carbozamtinib and nivolumab
Fig. 3: Typical sample chromatogram for carbozantinib and nivolumab
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Precision
The degree of the closeness of agreement among individual test results 
when a method is applied to multiple samplings of a homogeneous 
sample. It is a measure of either the degree of reproducibility 
(agreement under different conditions) or repeatability (agreement 
under the same conditions) of the method.
Accuracy
The closeness of results was obtained by a method to the true value. It 
is a measure of the exactness of the method.
Limit of detection (LOD) and limit of quantification (LOQ)
The detection limit and quantification limit for each analyte were 
determined based on a signal-to-noise concept, as the lowest 
concentration at which signal-to-noise ratio between 3 or 2:1 and 
10:1, respectively, with defined precision and accuracy under the given 
experimental conditions.
Stability
Standard and the sample solutions were subjected to 24 h stability 
studies at room temperature (RT) and 2–8°C. The stability of these 
solutions was studied and observed for changes in the area and 
retention time of the peaks which were then compared with the pattern 
of the chromatogram of the freshly prepared solution.
Robustness
Robustness of the method was studied by slightly changes in 
experimental conditions such as flow rate and organic composition. 
Robustness on performed same instrument with different chromatic 
conditions.
Ruggedness
Ruggedness of the method was studied using different source of 
analysts, instruments, and columns with same experimental conditions.
RESULTS AND DISCUSSION
Method validation
In this method, system suitability, linearity, precision, accuracy, 
robustness, LOD, LOQ, forced degradation, and stability are validated 
for the selected CZT and NVM drugs.
System suitability
200µg/ml of CZT and 50µg/ml of NVM was prepared and injected into 
the system. The retention times of CZT and NVM were found to be 3.418 
and 6.820 min, respectively. Resolution of the NVM was 8.36 from the 
CZT. The number of theoretical plate counts for CZT and NVM was 8560 
and 4836, respectively. Tailing factor for CZT and NVM was 0.46 and 
0.38, respectively. All the parameters found to be within the limit.
Linearity
Linearity of the method was evaluated by preparing a standard solution 
containing 200 µg/ml of CZT and 50 µg/ml of NVM (100% targeted level 
of the assay concentration). Sequential dilutions were performed to give 
solutions at 10, 25, 50, 100, 125, and 150% of the target concentrations. 
These were injected and peak areas used to plot calibration curves 
against the concentration. The correlation coefficient values of these 
three analytes were 0.999. The results are shown in Table 1.
LOD and LOQ
LOD and LOQ are the minimum concentration level at which the 
analyte can be reliably detected, quantified using the standard formulas 
(3.3 times σ/s and 10 times σ/s for LOD and LOQ, respectively). LOD 
values for CZT and NVM were 0.2 and 0.05 µg/ml and s/n values are 
4 and 7, respectively. LOQ values for CZT and NVM were 0.66 and 
0.165 µg/ml and s/n values are 25 and 28, respectively.
Precision
Method precision was investigated by the analysis of six separately 
prepared samples of the same batch. From this, six separate samples 
solution was injected and the peak areas obtained used to calculate 
mean and percentage relative standard deviation (%RSD) values. The 
present method was found to be precise as %RSD of <2%, and also, the 
percentage assay values were closed to be 100%. The results are given Fig. 4: Linearity plot for nivolumab
Fig. 5: Linearity plot for nivolumab
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in Table 2.
Accuracy
Accuracy was determined by recovery studies which were carried 
out in three different concentrations levels (50%, 100%, and 150%). 
APIs with concentration of 100, 200, and 300µg/ml of CZT and 25, 50, 
and 75 µg/ml of NVM were prepared. As per the test method, the test 
solution was injected three preparations each spike level and the assay 
was performed. The percentage of recovery values was found to be in 
the range of 100.14–100.26% of CZT and 100.54–100.72% of NVM. RSD 
values were found to be <2%. The results are given in Table 3.
Ruggedness
Ruggedness of the method was studied and showed that 
chromatographic patterns did not significantly change when different 
HPLC systems, analysts, and columns. The value of percentage of RSD 
was below 2% and exhibits the ruggedness of the developed method.
Robustness
Robustness of the method found to be %RSD should be <2%. Slight 
variations were done in the optimized method parameters such as flow 
rate (±20%) and organic content in mobile phase (±5%). The results 
are given in Table 4.
Stability
Stability of standard and sample solutions is studied initial to 24 h in 
stored RT and 2–8°C. These solutions are analyzed initial to 24h at 
different time intervals and results were recorded. The % deviation 
should not be more than 5.0%. There are no effects in storage conditions 
for CZT and NVM drugs. The results are shown in Table 5.
Forced degradation
Forced degradation conditions such as acidic, basic, oxidative, 
reduction, thermal, hydrolysis, and photolytic stresses were attempted 
as per the International Conference of Harmonization (ICH) guidelines 
Q2B. There is an effect of assay results. The results are shown in Table 6.
CONCLUSION
CZT and NVM are two drugs reported as novel and method is novel and 
is very strong discussion for the developed method in their validation. 
This method described the quantification of CZT and NVM in bulk and 
pharmaceutical formulation as per the ICH guidelines. The developed 
method was found to be accurate, precise, linear, and reliable. The 
advantage lies in the simplicity of sample preparation and economically 
fewer reagents were used. In addition, two compounds are eluted 
within 10 min. The proposed HPLC method was suitable resolution 
to precise quantification of the compounds. Statistical analysis of the 
experimental result indicates that the precision and reproducibility 
data are satisfactory. The developed chromatographic method can be 
effectively applied for routine analysis in drug research.
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